Clinical Trial
doi: 10.1016/j.transproceed.2004.11.041.
Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease
Affiliations
- PMID: 15848679
- DOI: 10.1016/j.transproceed.2004.11.041
Item in Clipboard
Clinical Trial
Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease
Transplant Proc.
2005 Mar.
Abstract
Hepatitis C virus (HCV) is the most common cause of end-stage liver disease in transplant recipients. Progression of recurrent HCV infection is accelerated. Cyclosporine is not only an immunosuppressive drug, but also an anti-HCV drug. We reported here the beneficial effect of combined interferon and cyclosporine treatment for chronic hepatitis C. We recommend this protocol for established HCV-related graft disease.
Similar articles
-
Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: experience in a single center.Transplant Proc. 2009 Apr;41(3):1041-3. doi: 10.1016/j.transproceed.2009.02.030. Transplant Proc. 2009. PMID: 19376421
-
Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience.Transplant Proc. 2006 May;38(4):1127-30. doi: 10.1016/j.transproceed.2006.02.135. Transplant Proc. 2006. PMID: 16757285
-
Amantadine monotherapy is ineffective in the treatment of hepatitis C virus recurrence in the post-liver transplantation setting.Transplant Proc. 2005 May;37(4):1705-7. doi: 10.1016/j.transproceed.2005.03.077. Transplant Proc. 2005. PMID: 15919438
-
Liver transplantation and hepatitis C.Transpl Int. 2002 Mar;15(2-3):61-72. doi: 10.1007/s00147-002-0382-4. Epub 2002 Mar 9. Transpl Int. 2002. PMID: 11935162 Review.
-
Course and treatment of recurrent Hepatitis C after liver transplantation.Minerva Gastroenterol Dietol. 2004 Mar;50(1):61-6. Minerva Gastroenterol Dietol. 2004. PMID: 15719007 Review.
Cited by
-
Cyclosporin a inhibits rotavirus replication and restores interferon-beta signaling pathway in vitro and in vivo.PLoS One. 2013 Aug 21;8(8):e71815. doi: 10.1371/journal.pone.0071815. eCollection 2013. PLoS One. 2013. PMID: 23990993 Free PMC article.
-
Profile of alisporivir and its potential in the treatment of hepatitis C.Drug Des Devel Ther. 2013;7:105-15. doi: 10.2147/DDDT.S30946. Epub 2013 Feb 15. Drug Des Devel Ther. 2013. PMID: 23440335 Free PMC article. Review.
-
Cyclophilin inhibitors as a novel HCV therapy.Viruses. 2010 Aug;2(8):1621-1634. doi: 10.3390/v2081621. Epub 2010 Aug 5. Viruses. 2010. PMID: 21994697 Free PMC article.
-
Host-targeting agents in the treatment of hepatitis C: a beginning and an end?Antiviral Res. 2013 Nov;100(2):555-61. doi: 10.1016/j.antiviral.2013.09.020. Epub 2013 Sep 30. Antiviral Res. 2013. PMID: 24091203 Free PMC article. Review.
-
Cyclophilin A as a New Therapeutic Target for Hepatitis C Virus-induced Hepatocellular Carcinoma.Korean J Physiol Pharmacol. 2013 Oct;17(5):375-83. doi: 10.4196/kjpp.2013.17.5.375. Epub 2013 Oct 17. Korean J Physiol Pharmacol. 2013. PMID: 24227937 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
